Nuvation Bio Inc.
IBTROZI
advanced ROS1+ NSCLC
Date
TBD
Approval decision · Date TBD estimated
What's at stake
A final FDA approval decision on IBTROZI for advanced ROS1+ NSCLC is expected Date TBD.
Primary source
· SEC 8-K
verified 15h ago
“Taletrectinib was included in China’s National Reimbursement Drug List effective January 1, 2026.”